BCTXZ
BriaCell Therapeutics Corp. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
1.63
52W High
$1.51
52W Low
$0.06
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies, primarily targeting breast cancer. Its lead product candidate, Bria-IMT, has shown promising efficacy in early clinical trials, highlighting the company’s potential to address significant unmet medical needs in oncology. With a robust research and development framework and an experienced leadership team, BriaCell is strategically positioned to make meaningful advancements in cancer treatment and improve patient outcomes within the rapidly evolving landscape of cancer therapeutics.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-30.63M |
| Operating Margin | 0.00% |
| Return on Equity | -179.20% |
| Return on Assets | -89.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.26 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $6.41M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/7/2026